{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Protein+Deficiency&page=2", "query": { "condition": "Protein Deficiency", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Protein+Deficiency&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T03:36:47.729Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00001026", "title": "A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "gp160 Vaccine (Immuno-AG)", "type": "BIOLOGICAL" }, { "name": "rgp120/HIV-1IIIB", "type": "BIOLOGICAL" }, { "name": "rgp120/HIV-1MN", "type": "BIOLOGICAL" }, { "name": "rgp120/HIV-1 SF-2", "type": "BIOLOGICAL" }, { "name": "HIVAC-1e", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 56, "start_date": null, "completion_date": "1994-12", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-06-10T03:36:47.729Z", "location_count": 2, "location_summary": "Rochester, New York • Seattle, Washington", "locations": [ { "city": "Rochester", "state": "New York" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001026" }, { "nct_id": "NCT00654004", "title": "Fatty Acid Oxidation Disorders & Body Weight Regulation Grant", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Trifunctional Protein Deficiency" ], "interventions": [], "intervention_types": [], "sponsor": "Oregon Health and Science University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "7 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "7 Years to 40 Years" }, "enrollment_count": 26, "start_date": "2006-04", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2013-04-22", "last_synced_at": "2026-06-10T03:36:47.729Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00654004" }, { "nct_id": "NCT00000884", "title": "A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "MN rgp120/HIV-1 and GNE8 rgp120/HIV-1", "type": "BIOLOGICAL" }, { "name": "ALVAC-HIV MN120TMG (vCP205)", "type": "BIOLOGICAL" }, { "name": "ALVAC-RG Rabies Glycoprotein (vCP65)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 84, "start_date": null, "completion_date": "2000-10", "has_results": false, "last_update_posted_date": "2021-10-29", "last_synced_at": "2026-06-10T03:36:47.729Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Rochester", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000884" }, { "nct_id": "NCT05411835", "title": "Oral Ketones and Exercise Among Patients With Long-chain Fatty Acid Oxidation Disorders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency", "Carnitine Palmitoyltransferase Deficiency 2", "Very Long Chain Acyl Coa Dehydrogenase Deficiency", "Trifunctional Protein Deficiency" ], "interventions": [ { "name": "Nutritional Ketone Supplement", "type": "DIETARY_SUPPLEMENT" }, { "name": "Isocaloric Placebo Supplement", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Oregon Health and Science University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2022-08-01", "completion_date": "2024-01-22", "has_results": false, "last_update_posted_date": "2024-04-02", "last_synced_at": "2026-06-10T03:36:47.729Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT05411835" }, { "nct_id": "NCT00137748", "title": "Cytomegalovirus Hyperimmune Globulin (CMV-Ig) Replacement in Hypogammaglobulinemic Lung Transplant Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Hypogammaglobulinemia" ], "interventions": [ { "name": "CMV-Ig", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Cleveland Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 50, "start_date": "2001-01", "completion_date": "2006-01", "has_results": false, "last_update_posted_date": "2010-06-10", "last_synced_at": "2026-06-10T03:36:47.729Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00137748" }, { "nct_id": "NCT04209634", "title": "Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "CD55-deficient Protein-losing Enteropathy", "CHAPLE" ], "interventions": [ { "name": "Pozelimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": null, "sex": "ALL", "summary": "1 Year and older" }, "enrollment_count": 10, "start_date": "2020-01-27", "completion_date": "2024-05-02", "has_results": true, "last_update_posted_date": "2025-08-29", "last_synced_at": "2026-06-10T03:36:47.729Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04209634" }, { "nct_id": "NCT01931644", "title": "At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "All Diagnosed Health Conditions", "ADD/ADHD", "Alopecia Areata", "Ankylosing Spondylitis", "Asthma", "Atopic Dermatitis Eczema", "Beta Thalassemia", "Bipolar Disorder", "Breast Cancer", "Celiac Disease", "Cervical Cancer", "Chronic Inflammatory Demyelinating Polyneuropathy", "Chronic Kidney Diseases", "Chronic Obstructive Pulmonary Disease", "Colon Cancer", "Colorectal Cancer", "Crohn's Disease", "Cystic Fibrosis", "Depression", "Diabetes Mellitus", "Duchenne Muscular Dystrophy", "Endometriosis", "Epilepsy", "Facioscapulohumeral Muscular Dystrophy", "G6PD Deficiency", "General Anxiety Disorder", "Hepatitis B", "Hereditary Hemorrhagic Telangiectasia", "HIV/AIDS", "Human Papilloma Virus", "Huntington's Disease", "Idiopathic Thrombocytopenic Purpura", "Insomnia", "Kidney Cancer", "Leukemia", "Lung Cancer", "Lupus Nephritis", "Lymphoma", "Melanoma", "Multiple Myeloma", "Multiple Sclerosis", "Myositis", "Myotonic Dystrophy", "Ovarian Cancer", "Pancreatic Cancer", "Parkinson's Disease", "Polycystic Kidney Diseases", "Prostate Cancer", "Psoriasis", "Psoriatic Arthritis", "Rosacea", "Scleroderma", "Sickle Cell Anemia", "Sickle Cell Trait", "Sjogren's Syndrome", "Skin Cancer", "Spinal Muscular Atrophy", "Systemic Lupus Erythematosus", "Thrombotic Thrombocytopenic Purpura", "Trisomy 21", "Ulcerative Colitis" ], "interventions": [], "intervention_types": [], "sponsor": "Sanguine Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 17667, "start_date": "2013-07", "completion_date": "2024-04", "has_results": false, "last_update_posted_date": "2024-04-18", "last_synced_at": "2026-06-10T03:36:47.729Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01931644" }, { "nct_id": "NCT00000847", "title": "A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "ALVAC-HIV MN120TMG (vCP205)", "type": "BIOLOGICAL" }, { "name": "ALVAC-RG Rabies Glycoprotein (vCP65)", "type": "BIOLOGICAL" }, { "name": "rgp120/HIV-1 SF-2", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 150, "start_date": null, "completion_date": "1999-05", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-06-10T03:36:47.729Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Rochester", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000847" }, { "nct_id": "NCT00001041", "title": "Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections", "Pregnancy" ], "interventions": [ { "name": "rgp120/HIV-1MN", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "40 Years", "sex": "FEMALE", "summary": "16 Years to 40 Years · Female only" }, "enrollment_count": 24, "start_date": null, "completion_date": "1998-07", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-06-10T03:36:47.729Z", "location_count": 6, "location_summary": "San Francisco, California • Baltimore, Maryland • St Louis, Missouri + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001041" }, { "nct_id": "NCT04910724", "title": "Effects of Varying Energy Deficits on Protein Turnover at Rest and Carbohydrate Oxidation During Steady-state Exercise", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Energy Supply; Deficiency, Severe", "Energy Supply; Deficiency", "Stress, Physiological" ], "interventions": [ { "name": "Energy Deficit", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "United States Army Research Institute of Environmental Medicine", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "35 Years", "sex": "ALL", "summary": "18 Years to 35 Years" }, "enrollment_count": 30, "start_date": "2022-08-16", "completion_date": "2024-03-07", "has_results": false, "last_update_posted_date": "2026-01-21", "last_synced_at": "2026-06-10T03:36:47.729Z", "location_count": 1, "location_summary": "Natick, Massachusetts", "locations": [ { "city": "Natick", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04910724" } ] }